AIKIDO PHARMA INC.

(AIKI)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Health Care Stocks Declining This Afternoon

01/24/2022 | 03:54pm EDT


ę MT Newswires 2022
Stocks mentioned in the article
ChangeLast1st jan.
AIKIDO PHARMA INC. -4.52% 0.3127 Delayed Quote.-44.21%
MEDIWOUND LTD. 2.26% 1.81 Delayed Quote.-23.31%
NASDAQ COMP. -4.73% 11418.15 Real-time Quote.-23.40%
OPKO HEALTH, INC. -7.74% 2.86 Delayed Quote.-40.54%
PFIZER, INC. -1.83% 50.4 Delayed Quote.-14.65%
TIZIANA LIFE SCIENCES PLC -5.54% 0.8501 Delayed Quote.-6.25%
All news about AIKIDO PHARMA INC.
05/16AIKIDO PHARMA INC. Management's Discussion and Analysis of Financial Condition and Res..
AQ
05/16AIkido Pharma Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
05/16NORTH AMERICAN MORNING BRIEFING : Stock Futures -3-
DJ
05/12AIkido Pharma Secures Interest in Databricks Inc.
PR
05/12AIkido Pharma Inc. acquired an unknown stake in Databricks, Inc.
CI
05/05AIkido Reports Slinger Bag Inc.'s Filing for Nasdaq Public Listing
PR
05/04AIkido Pharma Announces Strategic Investment in Social Communications Platform Provider..
PR
05/04Discord Inc. announced that it has received funding from AIkido Pharma Inc.
CI
04/22Glass Lewis Proxy Paper Report Recommends "FOR" AIkido Pharma Inc. Proposed Reverse Sto..
PR
04/05AIkido Pharma Announces Strategic Investment in MasterClass
PR
More news
Analyst Recommendations on AIKIDO PHARMA INC.
More recommendations
Financials (USD)
Sales 2022 - - -
Net income 2022 -11,5 M - -
Net Debt 2022 - - -
P/E ratio 2022 -2,41x
Yield 2022 -
Capitalization 27,9 M 27,9 M -
Capi. / Sales 2022 -
Capi. / Sales 2023 -
Nbr of Employees 5
Free-Float 99,8%
Chart AIKIDO PHARMA INC.
Duration : Period :
AIkido Pharma Inc. Technical Analysis Chart | AIKI | US0088751062 | MarketScreener
Technical analysis trends AIKIDO PHARMA INC.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 1
Last Close Price 0,31 $
Average target price 2,00 $
Spread / Average Target 540%
EPS Revisions
Managers and Directors
Anthony C. Hayes CEO, Chief Financial Officer & Director
Robert J. Vander Zanden Chairman
Timothy S. Ledwick Independent Director
Gregory James Blattner Independent Director
Paul LeMire Independent Director
Sector and Competitors
1st jan.Capi. (M$)
AIKIDO PHARMA INC.-44.21%29
MODERNA, INC.-45.78%56 593
LONZA GROUP AG-27.42%41 313
IQVIA HOLDINGS INC.-30.08%39 122
SEAGEN INC.-7.50%26 976
ICON PUBLIC LIMITED COMPANY-34.37%17 002